更新于：2024-11-01

CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR)

更新于：2024-11-01

概要

研发状态

概要

基本信息

药物类型

DNA疫苗、治疗性疫苗

别名

VLP-TBI-pcDNA-TCI

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

State Research Center of Virology and Biotechnology VECTOR

在研机构

State Research Center of Virology and Biotechnology VECTOR

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 79423

Sequence Code 1120173647

Sequence Code 107187

Sequence Code 36380

Sequence Code 1120173648

关联

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的临床结果

登录后查看更多信息

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的转化医学

登录后查看更多信息

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的专利（医药）

登录后查看更多信息

项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的文献（医药）

2008-02-01·Molecular Immunology3区 · 医学

A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins

3区 · 医学

Article

作者: Leonid R. Lebedev ; Roman V. Uzhachenko ; Sergei I. Bazhan ; Alexander A. Ilyichev ; Larisa I. Karpenko ; Alexey M. Eroshkin ; Pavel A. Belavin

Immunogenic properties of the combined vaccine CombiHIVvac, comprising polyepitope HIV-1 immunogens, one being the artificial polyepitope protein TBI, containing the T- and B-cell epitopes from Env and Gag proteins, and the DNA vaccine construct pcDNA-TCI coding for the artificial protein TCI, carrying over 80 T-cell epitopes (both CD4+ CTL and CD8+ Th) from Env, Gag, Pol, and Nef proteins, are studied in this work. The data reported demonstrate clearly that a combination of two B- and T-cell immunogens (TBI and TCI) in one construct results in a synergistic increase in the antibody response to both TBI protein and the proteins from HIV-1 lysate. The level of antibodies induced by immunization with the constructs containing either immunogen alone (TBI protein or the plasmid pcDNA-TCI) was significantly lower as compared to that induced by the combined vaccine. The analysis performed suggests that the presence of CD4+ T-helper epitopes, which can be presented by MHC class II, in the protein TCI may be the main reason underlying the increased synthesis of antibodies to TBI protein due to a CD4-mediated stimulation of B-cell proliferation and differentiation.

2007-05-01·Vaccine3区 · 医学

Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine

3区 · 医学

Article

作者: Sergei I. Bazhan ; Sergei V. Seregin ; Leonid R. Lebedev ; Roman V. Uzhachenko ; Elena D. Danilenko ; Alexander A. Ilyichev ; Olga A. Plyasunova ; Nadezhda K. Danilyuk ; Larisa I. Karpenko ; Valentina I. Masycheva ; Alexey M. Eroshkin ; Nadezhda A. Nekrasova ; Pavel A. Belavin ; Boris N. Zaitsev

We have previously described designing of polyepitope immunogens TBI and TCI, to stimulate the humoral and cellular immune responses to HIV-1. Here, immunogens TBI and TCI were used to create new vaccine construct named CombiHIVvac (Combined HIV-1 vaccine). CombiHIVvac is a virus-like particles (VLP) containing the DNA vaccine pcDNA-TCI as a core encapsulated within a spermidine-polyglucin-TBI conjugate. The immunogenic and toxic properties of the candidate vaccine CombiHIVvac have been studied. CombiHIVvac induces a strong humoral and CTL responses in mice; the antibodies are highly specific and are able to neutralize HIV-1 in vitro. Preclinical study demonstrated that CombiHIVvac does not cause long-term changes in physiological, biochemical and morphological parameters in immunized animals and thus can be recommended for clinical trials.

2004-04-01·Vaccine3区 · 医学

Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens

3区 · 医学

Article

作者: Sergei V Seregin ; Sergei I Bazhan ; Vera A Poryvaeva ; George M Ignatyev ; Nadezhda A Nekrasova ; Irina V Aborneva ; Alexander P Agafonov ; Pavel A Belavin ; Irina N Babkina ; Alexander A Ilyichev ; Larisa I Karpenko ; Leonid R Lebedev ; Nadezhda K Danilyuk

A synthetic T cell immunogen (TCI) has been designed as a candidate DNA-based vaccine against Human immunodeficiency virus (HIV)-1 using cytotoxic T lymphocytes (CD8(+) CTL) and T-helper lymphocytes (CD4(+) Th) epitopes retrieved from the Los Alamos HIV Molecular Immunology Database. The protein 392 amino acids in length contains about eighty CTL-epitopes, many of which are overlapping and are totally restricted by ten different HLA class I molecules. To be able to detect CTL responses induced by a DNA vaccine in experimental animals, additional epitopes, restricted by mouse and Macaque rhesus major histocompatibility complex (MHC) class I molecules, were included in the target immunogen. The gene encoding the TCI protein was assembled, cloned into vector plasmids and expressed in a prokaryotic and a eukaryotic system. The presence of HIV-1 protein fragments in the immunogen structure was ascertained by ELISA and immunoblotting using panels of HIV-1-positive sera and monoclonal antibodies to p24. It has been demonstrated that DNA vaccine can induce both specific T cell responses (CTL and blast transformation) and specific antibodies in mice immunized with pcDNA-TCI.

项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的新闻（医药）

2023-02-13

·Coatings World

PCI Announces 2023 Board of Directors and Executive Officers

The Powder Coating Institute (PCI) announces its 2023 Board of Directors and Executive Officers. PCI values the support of its member companies and is very fortunate to have the leadership of the following individuals: • President: Shelley Verdun, business manager, powder coatings – Americas region, PPG • Vice President: Tom Whalen, vice president sales & marketing, TCI Powder Coatings • Secretary/Treasurer: Bob Cregg, business director North America, Covestro Coating Resins, Inc. • Past President: Chris Merritt, vice president of Gema North America, Gema USA, Inc. “I am looking forward to working with the 2023 PCI Board of Directors on our mission to promote and grow the powder coating market,” said PCI executive director Kevin Coursin. “We are lucky to have three past board members who have been re-elected and one brand-new board member. Their guidance and planning for improving all the PCI programs and initiatives will be greatly appreciated” PCI welcomes new board member Tabitha McLeish, global marketing director-powder, general industrial coatings, Sherwin-Williams Company. “As a newly elected PCI board member, I am very excited for the opportunity to share my passion about powder, help bring together powder coating industry professionals to exchange ideas and develop solutions, and contribute to PCI’s mission of communicating the sustainability, durability, and cost-efficiency benefits of powder coating technology to the industry,” McLeish said. Continuing their commitment on the PCI Board of Directors for 2023, the following individuals provide support and service to benefit the powder coating industry on every level: David Flatten, president and CEO, Inland Powder Coating; Teddy Piepkow, Central US & Canada powder sales manager, Nordson Corporation; Marty Sawyer, CEO, Trimac Industrial Systems, LLC; John Sudges, sales manager, Midwest Finishing Systems, Inc.; Mike Withers, architectural segment leader, Axalta Coating Systems; and Mark Ziehm, senior technology manager, Henkel Corporation.

高管变更

100 项与 CombiVICHvac(State Research Center of Virology and Biotechnology VECTOR) 相关的药物交易

登录后查看更多信息